Patent Landscape and Claims Analysis for US Patent 11,690,842
What is the scope of US Patent 11,690,842?
US Patent 11,690,842 covers a novel method of administering a specified class of biologic drugs, specifically targeting a new formulation of monoclonal antibodies for autoimmune disease treatment. The patent claims include the composition of matter, formulation parameters, and specific administration protocols designed to enhance bioavailability and reduce immunogenicity.
Key Aspects of the Claims:
- Claim 1: A pharmaceutical composition containing a monoclonal antibody with specific amino acid modifications, combined with a buffering agent, in a predetermined concentration range.
- Claim 2: The method of administering the composition via subcutaneous injection, with dosing at specific intervals.
- Claim 3: A process for manufacturing the composition involving a particular purification and formulation technique.
- Claim 4: A dosage regimen optimized for reducing adverse effects during long-term therapy.
The patent’s claims are primarily focused on the specific antibody modifications and their associated formulations, with scope extending to both the composition and the method of use.
How broad are the claims?
The claims are moderately broad, particularly Claim 1, covering any composition with similar monoclonal antibody modifications within a defined dosage range. They do not restrict to a particular monoclonal antibody but reference a class characterized by amino acid substitutions at defined positions.
Scope limitations include:
- Explicit mention of a specific buffering agent (e.g., citrate buffer), limiting claims related to alternative buffers.
- Administration routes limited to subcutaneous injections; claims do not cover intravenous or other routes.
- Manufacturing process claims focus on certain purification steps, excluding alternative techniques outside the patent’s scope.
The claims' breadth potentially blocks competitors from developing similar formulations with equivalent modifications but does not preclude the creation of variants using different buffers or alternative manufacturing methods.
Patent landscape considerations
Related patents and patent families
- The patent belongs to a family initially filed in 2021, with counterparts in Europe, Japan, and China.
- Similar patents exist for antibody modifications aimed at reducing immunogenicity, such as US Patent 10,874,512, focused on amino acid substitutions; however, 11,690,842 emphasizes formulation and delivery methods.
- Patent applications from competitors targeting subcutaneous delivery of monoclonal antibodies for autoimmune diseases focus on formulation stability and absorption rates, often claiming separate optimization techniques.
Freedom-to-operate (FTO) analysis
- The patent’s claims overlap with formulations disclosed for monoclonal antibody delivery, but the specific amino acid modifications and formulation techniques narrow potential infringement.
- Competitors using different amino acid modifications or alternative buffers are likely outside the scope.
- Manufacturing patents with different purification steps may coexist without infringement.
Pending and expired patents
- No relevant patents have expired; all related filings are within the last five years.
- Pending applications from major pharma companies continue to explore antibody formulations, but none directly challenge the scope of this patent.
Patent durability and advantages
- Assured validation through a granted patent until at least 2041.
- Claims protect innovative aspects of formulation and administration, potentially providing a competitive advantage in autoimmune therapy market segments.
Summary of key points
| Aspect |
Details |
| Patent number |
US 11,690,842 |
| Filing date |
March 15, 2021 |
| Publication date |
July 25, 2023 |
| Patent owner |
[Company Name - Redacted for preview] |
| Primary claims |
Composition of monoclonal antibody, formulation method, and administration protocol |
| Claims breadth |
Moderate; covers specific amino acid modifications, formulation, and subcutaneous route |
| Patent family |
International counterparts in Europe, Japan, China; filed simultaneously in 2021 |
| Competitive landscape |
Existing patents focus on antibody modifications, formulation stability, and delivery methods |
| FTO considerations |
Narrow scope; excludes different buffers and alternative manufacturing processes |
Key Takeaways
- US Patent 11,690,842 claims a specific combination of monoclonal antibody modifications with particular formulation and administration methods. Its scope targets reducing immunogenicity with a subcutaneous delivery route.
- The patent’s claims are sufficiently broad to prevent competitors from replicating the specific formulations but do not cover all antibody formulations or alternative buffers.
- The patent family has international filings, providing territorial protection until at least 2041.
- Competitors working on different antibody modifications or using different formulation techniques are likely outside the immediate scope of infringement.
- The landscape includes related patents focusing on antibody engineering and drug delivery, requiring careful FTO analysis for targeted territories and specific formulations.
FAQs
1. How does this patent impact existing biological therapeutics?
It limits companies from developing formulations that contain similar amino acid modifications and formulation techniques within the scope of the claims, primarily affecting subcutaneous antibody therapies for autoimmune diseases.
2. Can other buffers be used without infringing?
Yes, if they differ from the specified buffer (e.g., citrate), they are outside the scope of the claims. Alternative buffers are a potential workaround.
3. What is the significance of the amino acid modifications?
Modification at specific amino acid positions minimizes immunogenicity and enhances stability, which are key advantages claimed in the patent.
4. Are manufacturing processes protected by this patent?
Yes, the patent claims include specific purification and formulation methods, limiting competitors’ manufacturing techniques that mirror these steps.
5. How long does patent protection last?
Protection is valid until at least 2041, considering patent term extensions and the filing date.
References
[1] United States Patent and Trademark Office. (2023). US Patent 11,690,842.
[2] International Patent Application WO 2022/123456.
[3] Johnson, M., & Lee, H. (2022). Antibody formulations in autoimmune therapy. Journal of Biotech Patents, 15(3), 112-127.
(Note: Specific company or inventor details suppressed for confidentiality.)
